Webinar | Women’s Nutrition: Nourishing Womanhood From Pregnancy To Menopause
11 September | 12 PM ET: Register Now

Imaginostics

Imaginostics is creating the next generation of precision medicine diagnostic and prognostic tools.
2018
02-Oct
02-10
Orlando, Florida, United States
  • Drug Discovery and Development
  • Medical Imaging and Visualization Technology

Innovation

Industry Problem

Genomic and biomarker data are complex and are not consistently converted into clear, patient-specific diagnostic or treatment decisions.

R&D Focus

AI-assisted medical imaging and quantitative diagnostics

Innovative Solution

Imaginostics is creating the next generation of precision medicine diagnostic and prognostic tools to serve clinicians and drug developers to transform personalized healthcare, accelerate drug development, and fight aging. Our proprietary MRI physics-based technology delivers 10X better vascular images and quantitative measurements for vascular structure, function, and leakage.

Solution Effectiveness

Our proprietary MRI physics-based technology delivers 10X better vascular images and quantitative measurements for vascular structure, function, and leakage.

Investment Funding

Last Funding Stage

Seed

Total Funding Amount

8.43M

Last Funding Amount

5.3M

Last Funding Date

01-06-2024

Startup Stage

Seed

Lead Investors

Ideaship, Alzheimer's Drug Discovery Foundation, National Institute on Aging, National Institute of Mental Health

Revenue

$1M to $10M

People

Founders

About

Imaginostics is creating the next generation of precision medicine diagnostic and prognostic tools to serve clinicians and drug developers to transform personalized healthcare, accelerate drug development, and fight aging. Our proprietary MRI physics-based technology delivers 10X better vascular images and quantitative measurements for vascular structure, function, and leakage. Our technology and software are compatible with existing MRI scanners, and as a bonus, is compatible with safe iron supplement for contrast (not toxic gadolinium). We provide biomarker solutions through CROs to pharma and participate in pre-clinical and clinical research in a variety of focus areas collaborating with world-renowned researchers at leading institutions. To learn more, please visit: http://www.imaginostics.com

Something missing or incorrect on this page? Help us enrich this information